RNAC
Selecta Biosciences Inc

7,727
Mkt Cap
$185.93M
Volume
115,012.00
52W High
$26.50
52W Low
$5.98
PE Ratio
-0.14
RNAC Fundamentals
Price
$7.15
Prev Close
$7.15
Open
$7.31
50D MA
$8.99
Beta
1.82
Avg. Volume
130,697.17
EPS (Annual)
-$4.48
P/B
-5.19
Rev/Employee
$589,590.91
Loading...
Loading...
News
all
press releases
HC Wainwright Issues Pessimistic Forecast for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price
HC Wainwright cut their price target on Cartesian Therapeutics from $40.00 to $30.00 and set a "buy" rating for the company in a report on Wednesday...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Given New $44.00 Price Target at BTIG Research
BTIG Research increased their price objective on Cartesian Therapeutics from $42.00 to $44.00 and gave the company a "buy" rating in a research note on Friday...
MarketBeat·5d ago
News Placeholder
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.read more...
Benzinga·6d ago
News Placeholder
Cantor Fitzgerald Issues Negative Estimate for RNAC Earnings
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Cartesian Therapeutics in a research report issued to...
MarketBeat·7d ago
News Placeholder
Wedbush Has Negative Forecast for RNAC FY2025 Earnings
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at Wedbush cut their FY2025 earnings estimates for shares of Cartesian Therapeutics in a note issued to investors on...
MarketBeat·11d ago
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results, Misses Estimates By $0.57 EPS
Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) announced its earnings results on Thursday. The company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·12d ago
News Placeholder
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +9.52% and +4.18%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23d ago
News Placeholder
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
Cartesian Therapeutics, Inc. (RNAC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago
News Placeholder
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·4mo ago
News Placeholder
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·5mo ago

Latest RNAC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.